Karolinska Development AB (publ) (KDEV.ST) Research

Karolinska Development AB (publ) functions as a venture capital firm, dedicating its capital to companies across various development stages, including seed, early, and growth phases. The company's investment strategy concentrates on a broad spectrum of life science and healthcare sectors, such as pharmaceutical and medical research and development, healthcare technology, gene research, advanced drug delivery solutions, biotechnology, and life science tools and services. Geographically, the firm prioritizes the Nordic region, specifically seeking opportunities within Sweden, Iceland, Norway, Finland, and Denmark. While it primarily aims to be the principal investor in its portfolio companies, it also considers collaborative investments. On an annual basis, Karolinska Development AB (publ) targets engaging in up to five new projects. The company was established in 2003 and is headquartered in Stockholm, Sweden.

Market snapshot

Symbol
KDEV.ST
Price
$0.28
Day change
-1.59%
Market cap
$75.3M
P/E ratio
-0.39x
52-week range
0.2205-1.344
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AlzeCure Pharma AB (publ) (ALZCUR.ST)
  • Annexin Pharmaceuticals AB (publ) (ANNX.ST)
  • Bio-Works Technologies AB (publ) (BIOWKS.ST)
  • Boule Diagnostics AB (publ) (BOUL.ST)
  • Initiator Pharma A/S (INIT.ST)
  • IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
  • Isofol Medical AB (publ) (ISOFOL.ST)
  • Lipum AB (publ) (LIPUM.ST)

Open Karolinska Development AB (publ) (KDEV.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.